
Please try another search
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Stefan Ross | - | 2021 | Non-Executive Director & Company Secretary |
Allen Ebens | - | 2016 | Member of Scientific Advisory Board |
James A. Campbell | - | 2014 | Non-Executive Director |
Peter Ordentlich | 56 | 2020 | Member of Scientific Advisory Board |
Peter James Christie | 63 | 2025 | Non-Executive Chairman |
Anton Uvarov | - | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review